EU Commission's Attack On Pharma Pay-For-Delay “Is Misguided”
This article was originally published in The Pink Sheet Daily
Executive Summary
The EU Commission's assumption that pharma pay-for-delay settlements are anti-competitive is by no means water-tight, a senior IP and competition lawyer suggests.
You may also be interested in...
EU Commission Misses Chance To Offer Guidance On Patent Settlements
The European Commission has published its fourth report in monitoring patent settlements, but again has failed to offer pharma companies guidance on how to avoid potential competition abuses.
Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.